Aspirin in the chemoprevention of colorectal neoplasia: an overview.
Considerable evidence supports the effectiveness of aspirin for chemoprevention of colorectal cancer (CRC) in addition to its well-established benefits in the prevention of vascular disease. Epidemiologic studies have consistently observed an inverse association between aspirin use and risk of CRC....
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1826286608340484096 |
|---|---|
| author | Chan, A Arber, N Burn, J Chia, W Elwood, P Hull, M Logan, R Rothwell, P Schrör, K Baron, J |
| author_facet | Chan, A Arber, N Burn, J Chia, W Elwood, P Hull, M Logan, R Rothwell, P Schrör, K Baron, J |
| author_sort | Chan, A |
| collection | OXFORD |
| description | Considerable evidence supports the effectiveness of aspirin for chemoprevention of colorectal cancer (CRC) in addition to its well-established benefits in the prevention of vascular disease. Epidemiologic studies have consistently observed an inverse association between aspirin use and risk of CRC. A recent pooled analysis of a long-term posttrial follow-up of nearly 14,000 patients from four randomized, cardiovascular disease prevention trials showed that daily aspirin treatment for about five years was associated with a 34% reduction in 20-year CRC mortality. A separate metaanalysis of nearly 3,000 patients with a history of colorectal adenoma or cancer in four randomized adenoma prevention trials showed that aspirin reduced the occurrence of advanced adenomas by 28% and any adenoma by 17%. Aspirin has also been shown to be beneficial in a clinical trial of patients with Lynch syndrome, a hereditary CRC syndrome; in those treated with aspirin for at least two years, there was a 50% or more reduction in the risk of CRC commencing five years after randomization and after aspirin had been discontinued. A few observational studies have shown an increase in survival among patients with CRC who use aspirin. Taken together, these findings strengthen the case for consideration of long-term aspirin use in CRC prevention. Despite these compelling data, there is a lack of consensus about the balance of risks and benefits associated with long-term aspirin use, particularly in low-risk populations. The optimal dose to use for cancer prevention and the precise mechanism underlying aspirin's anticancer effect require further investigation. |
| first_indexed | 2024-03-07T01:46:16Z |
| format | Journal article |
| id | oxford-uuid:9887e304-16d1-4b7f-b163-18ae67a7740d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:46:16Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:9887e304-16d1-4b7f-b163-18ae67a7740d2022-03-27T00:07:37ZAspirin in the chemoprevention of colorectal neoplasia: an overview.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:9887e304-16d1-4b7f-b163-18ae67a7740dEnglishSymplectic Elements at Oxford2012Chan, AArber, NBurn, JChia, WElwood, PHull, MLogan, RRothwell, PSchrör, KBaron, JConsiderable evidence supports the effectiveness of aspirin for chemoprevention of colorectal cancer (CRC) in addition to its well-established benefits in the prevention of vascular disease. Epidemiologic studies have consistently observed an inverse association between aspirin use and risk of CRC. A recent pooled analysis of a long-term posttrial follow-up of nearly 14,000 patients from four randomized, cardiovascular disease prevention trials showed that daily aspirin treatment for about five years was associated with a 34% reduction in 20-year CRC mortality. A separate metaanalysis of nearly 3,000 patients with a history of colorectal adenoma or cancer in four randomized adenoma prevention trials showed that aspirin reduced the occurrence of advanced adenomas by 28% and any adenoma by 17%. Aspirin has also been shown to be beneficial in a clinical trial of patients with Lynch syndrome, a hereditary CRC syndrome; in those treated with aspirin for at least two years, there was a 50% or more reduction in the risk of CRC commencing five years after randomization and after aspirin had been discontinued. A few observational studies have shown an increase in survival among patients with CRC who use aspirin. Taken together, these findings strengthen the case for consideration of long-term aspirin use in CRC prevention. Despite these compelling data, there is a lack of consensus about the balance of risks and benefits associated with long-term aspirin use, particularly in low-risk populations. The optimal dose to use for cancer prevention and the precise mechanism underlying aspirin's anticancer effect require further investigation. |
| spellingShingle | Chan, A Arber, N Burn, J Chia, W Elwood, P Hull, M Logan, R Rothwell, P Schrör, K Baron, J Aspirin in the chemoprevention of colorectal neoplasia: an overview. |
| title | Aspirin in the chemoprevention of colorectal neoplasia: an overview. |
| title_full | Aspirin in the chemoprevention of colorectal neoplasia: an overview. |
| title_fullStr | Aspirin in the chemoprevention of colorectal neoplasia: an overview. |
| title_full_unstemmed | Aspirin in the chemoprevention of colorectal neoplasia: an overview. |
| title_short | Aspirin in the chemoprevention of colorectal neoplasia: an overview. |
| title_sort | aspirin in the chemoprevention of colorectal neoplasia an overview |
| work_keys_str_mv | AT chana aspirininthechemopreventionofcolorectalneoplasiaanoverview AT arbern aspirininthechemopreventionofcolorectalneoplasiaanoverview AT burnj aspirininthechemopreventionofcolorectalneoplasiaanoverview AT chiaw aspirininthechemopreventionofcolorectalneoplasiaanoverview AT elwoodp aspirininthechemopreventionofcolorectalneoplasiaanoverview AT hullm aspirininthechemopreventionofcolorectalneoplasiaanoverview AT loganr aspirininthechemopreventionofcolorectalneoplasiaanoverview AT rothwellp aspirininthechemopreventionofcolorectalneoplasiaanoverview AT schrork aspirininthechemopreventionofcolorectalneoplasiaanoverview AT baronj aspirininthechemopreventionofcolorectalneoplasiaanoverview |